Treatment of acquired reactive perforating collagenosis with dupilumab in a patient with end‐stage renal disease

Lee, Yu Jin; Lee, June Hyunkyung; Choi, Jae Eun; Han, Tae Young

doi:10.1111/dth.15926

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports of six cases showed partial improvement of itch NRS as well as resolution of skin lesions under dupilumab treatment. Notably, three patients had no history of AD or atopy ( Table 2 ) [ 95 , 96 , 97 , 98 , 99 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Dupilumab, which is a fully human monoclonal antibody against interleukin‐4 receptor α (IL‐4Rα), effectively treats pruritic disorders. Our research group first reported the successful use of Dupilumab for the treatment of ARPC last year ( 12 ), subsequently, scholars from South Korea, Saudi Arabia, and Spain have also demonstrated therapeutic effects of dupilumab for ARPC ( 13 – 15 ), suggesting the involvement of Th2 inflammation in the pathophysiology of the disease.…”

Section: Introductionmentioning

confidence: 99%

Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation

Liu,

Wu,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAcquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis.ObjectiveTo evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions.MethodsThis retrospective cohort study included 20 patients with ARPC; 10 received dupilumab and 10 received conventional therapy. The efficacy and safety of dupilumab were evaluated at 12 weeks. Immunohistochemical and immunofluorescence analyses of T- and B-cell markers, and type 2 inflammation-related cytokines, were performed on skin samples from ARPC patients, atopic dermatitis (AD) patients, and healthy controls.ResultsSignificantly more patients showed improvements in the Investigator Global Assessment score (100% vs. 0%; p < 0.0001) and itching (90%/8.33%, P =.001) in the dupilumab group compared to the conventional group at 12 weeks. There were no adverse effects in the dupilumab group. The ARPC lesions showed enhanced dermal infiltration of CD3+ T-cells, with a predominance of Th2 cells, similar to AD lesions. IL-4 and IL-13 were co-localized with GATA3 in ARPC lesions.ConclusionDupilumab improved ARPC charaterized with type 2 inflammation.

show abstract